References
- Agha MA, El-Habashy MM, El-Shazly RA (2014). Role of fibulin-3 in the diagnosis of malignant mesothelioma. Egyptian J Chest Diseases Tuberculosis, 63, 99-105. https://doi.org/10.1016/j.ejcdt.2013.10.004
- Antman KH (1993). Natural history and epidemiology of malignant mesothelioma. Chest, 103, 373-6. https://doi.org/10.1378/chest.103.4_Supplement.373S
- Berk S, Dogan OT, Kilickap S, et al (2013). Clinical characteristics, treatment and survival outcomes in malignant mesothelioma: Eighteen years' experience in Turkey. Asian Pac J Cancer Prev, 13, 5735-9.
- Boutin C, Rey F, Gouvernet J, et al (1993). Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer, 72, 394-404. https://doi.org/10.1002/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5
- Creaney J, Robinson BW (2009). Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med, 15, 366-70. https://doi.org/10.1097/MCP.0b013e32832b98eb
- Creaney J, Dick IM, Meniawy TM, et al (2014). Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax, 69, 895-902. https://doi.org/10.1136/thoraxjnl-2014-205205
- Edwards JG, Abrams KR, Leverment JN, et al (2000). Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax, 55, 731-5. https://doi.org/10.1136/thorax.55.9.731
- Hefler LA, Concin N, Hofstetter G, et al (2008). Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res, 14, 710-4. https://doi.org/10.1158/1078-0432.CCR-07-1044
- Hollevoet K, Reitsma JB, Creaney J, et al (2012). Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol, 30, 1541-9. https://doi.org/10.1200/JCO.2011.39.6671
- Hu B, Thirtamara-Rajamani KK, Sim H, Viapiano MS (2009). Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res, 7, 1756-70. https://doi.org/10.1158/1541-7786.MCR-09-0207
- Kim EJ, Lee SY, Woo MK, et al (2012). Fibulin-3 promoter methylation alters the invasive behavior of non-small cell lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol, 40, 402-8.
- Kim YJ, Yoon HY, Kim SK, et al (2011). EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res, 17, 4523-30. https://doi.org/10.1158/1078-0432.CCR-10-2817
- Komurcuoglu B, Cirak AK, Kirakli SC, et al (2014). Prognostic factors affecting survival in malignant pleural mesothelioma: analysis of 125 subjects. Tumori, 100, 55-9.
- Metintas M, Metintas S, Ucgun I, et al (2001). Prognostic factors in diffuse malignant pleural mesothelioma: pretreatment clinical and laboratory characteristics. Respir Med, 95, 829-35. https://doi.org/10.1053/rmed.2001.1178
- Metintas M, Metintas S, Ak G, et al (2008). Epidemiology of pleural mesothelioma in a population with non-occupational asbestos exposure. Respirology, 13, 117-21. https://doi.org/10.1111/j.1440-1843.2007.01187.x
- Metintas S, Metintas M, Ucgun I, Oner U (2002). Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest, 122, 2224-9. https://doi.org/10.1378/chest.122.6.2224
- Nojiri S, Gemba K, Aoe K, et al (2011). Survival and Prognostic Factors in Malignant Pleural Mesothelioma: A Retrospective Study of 314 patients in the West Part of Japan. Jpn J Clin Oncol, 41, 32-9. https://doi.org/10.1093/jjco/hyq159
- Nomoto S, Kanda M, Okamura Y, et al (2010). Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol, 17, 923-32. https://doi.org/10.1245/s10434-009-0790-0
- O'Dowd C, McRae LA, McMillan DC, Kirk A, Milroy R (2010). Elevated preoperative C- reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol, 5, 988-92. https://doi.org/10.1097/JTO.0b013e3181da78f9
- Ordonez NG (2003). The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol, 27, 1031-51. https://doi.org/10.1097/00000478-200308000-00001
- Pass HI, Levin SM, Harbut MR, et al (2012). Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med, 367, 1417-27. https://doi.org/10.1056/NEJMoa1115050
- Pierce BL, Ballard-Barbash R, Bernstein L, et al (2009). Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol, 27, 3437-44. https://doi.org/10.1200/JCO.2008.18.9068
- Rusch VW, Venkatraman ES (1999). Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg, 68, 1799-804. https://doi.org/10.1016/S0003-4975(99)01038-3
- Senyigit A, Babayigit C, Gokirmak M, et al (2000). Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey. Respiration, 67, 610-4. https://doi.org/10.1159/000056289
- Tanrikulu AC, Abakay A, Kaplan MA, et al (2010). A clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma. Respiration, 80, 480-7. https://doi.org/10.1159/000321370
- Teta MJ, Mink PJ, Lau E, Sceurman BK, Foster ED (2008). US mesothelioma patterns 1973-2002: indicators of change and insights into background rates. Eur J Cancer Prev, 17, 525-34. https://doi.org/10.1097/CEJ.0b013e3282f0c0a2
- Tong JD, Jiao NL, Wang YX, Zhang YW, Han F (2011). Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis. Neoplasma, 58, 441-8. https://doi.org/10.4149/neo_2011_05_441
- Van Gelder T, Damhuis RAM, Hoogsteden HC (1994). Prognostic factors and survival in malignant pleural mesothelioma. Eur Respir J, 7, 1035-38.
- Vogelzang NJ, Rusthoven JJ, Symanowski J, et al (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 21, 2636-44. https://doi.org/10.1200/JCO.2003.11.136
- Wang CS, Sun CF (2009). C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J, 32, 471-82.
- Zhang Y, Marmorstein LY (2010). Focus on molecules: fibulin-3 (EFEMP1). Exp Eye Res, 90, 374-5. https://doi.org/10.1016/j.exer.2009.09.018
Cited by
- tumor predisposition syndrome with report of two new cases vol.89, pp.3, 2016, https://doi.org/10.1111/cge.12630
- Prognostication and monitoring of mesothelioma using biomarkers: a systematic review vol.116, pp.6, 2017, https://doi.org/10.1038/bjc.2017.22
- FBLN-3 as a biomarker of pleural plaques in workers occupationally exposed to carcinogenic fibers: a pilot study vol.11, pp.24s, 2015, https://doi.org/10.2217/fon.15.271
- Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on vol.10, pp.6, 2018, https://doi.org/10.3390/cancers10060203
- Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline vol.36, pp.13, 2018, https://doi.org/10.1200/JCO.2017.76.6394